Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) & RYTHM (NASDAQ:RYM) Financial Contrast

RYTHM (NASDAQ:RYM – Get Free Report) and Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends.

Profitability

This table compares RYTHM and Shionogi & Co., Ltd. Unsponsored ADR’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
RYTHM 9.84% 21.25% 5.51%
Shionogi & Co., Ltd. Unsponsored ADR 37.95% 14.32% 10.24%

Analyst Ratings

This is a summary of recent ratings and price targets for RYTHM and Shionogi & Co., Ltd. Unsponsored ADR, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RYTHM 1 0 0 0 1.00
Shionogi & Co., Ltd. Unsponsored ADR 0 0 0 3 4.00

Earnings & Valuation

This table compares RYTHM and Shionogi & Co., Ltd. Unsponsored ADR”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
RYTHM $70.82 million 0.38 -$33.26 million ($5.27) -2.32
Shionogi & Co., Ltd. Unsponsored ADR $3.32 billion 5.13 $1.35 billion $0.90 11.12

Shionogi & Co., Ltd. Unsponsored ADR has higher revenue and earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than Shionogi & Co., Ltd. Unsponsored ADR, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

6.0% of RYTHM shares are owned by institutional investors. Comparatively, 1.9% of Shionogi & Co., Ltd. Unsponsored ADR shares are owned by institutional investors. 3.5% of RYTHM shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

RYTHM has a beta of 9.94, meaning that its share price is 894% more volatile than the S&P 500. Comparatively, Shionogi & Co., Ltd. Unsponsored ADR has a beta of 0.1, meaning that its share price is 90% less volatile than the S&P 500.

Summary

Shionogi & Co., Ltd. Unsponsored ADR beats RYTHM on 9 of the 13 factors compared between the two stocks.

About RYTHM

(Get Free Report)

I couldn’t verify a Nasdaq-listed company named RYTHM with the ticker RYM. If you mean Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM), it is a biopharmaceutical company developing treatments for rare genetic diseases and other conditions linked to the brain’s melanocortin-4 receptor pathway, which helps regulate hunger and body weight. Its marketed medicine, Imcivree (setmelanotide), is approved in the United States for certain forms of rare genetic obesity and acquired hypothalamic obesity. The company is based in Boston and focuses on developing and providing therapies for patients in the United States and other markets.

About Shionogi & Co., Ltd. Unsponsored ADR

(Get Free Report)

Shionogi & Co., Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Founded in Osaka in 1878, it has grown from a pharmaceutical wholesaler into a research-focused drugmaker. The company has a particular focus on infectious diseases, including HIV, influenza and COVID-19, and also works in areas such as pain and central nervous system disorders. Its products include Xofluza, an influenza treatment, and ensitrelvir, an oral COVID-19 antiviral marketed in Japan as Xocova.

Receive News & Ratings for RYTHM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RYTHM and related companies with MarketBeat.com's FREE daily email newsletter.